HOME >> MEDICINE >> NEWS
Failed lung cancer drug could help shrink breast tumors

Giving women with early breast cancer a drug called gefitinib (Iressa) before surgery could reduce the size of their tumours, suggests a randomised trial published online today (Tuesday May 17, 2005) by THE LANCET ONCOLOGY. Gefitinib has been tested in clinical trials as a treatment for lung cancer but did not help patients live longer overall. Large-scale studies to assess its use in breast cancer, as a treatment prior to surgery, are now being designed, state the authors.

Some breast cancers are hormone sensitive and proliferate in the presence of oestrogen. But in trials where women with this type of breast cancer were given pre-surgical treatment to block hormones only half were found to respond. For this reason many doctors use chemotherapy prior to surgery, which can have negative side effects and cause substantial mortality.

A receptor called EGFR (epidermal growth factor receptor) is present on some hormone sensitive breast cancers and is associated with poor prognosis and failure to respond to hormone-blocking therapy. Charles Coombes (Imperial College and Hammersmith Hospital, London, UK) and colleagues tested whether inhibiting this receptor with a drug called gefitinib might suppress breast cancer cell proliferation. They recruited 56 postmenopausal women with breast cancer that was hormone sensitive and positive for EGFR from hospitals in London. 27 women were assigned gefitinib and an aromatase inhibitor called anastrozole (Arimidex) and 29 were assigned gefitinib and placebo for 4-6 weeks prior to receiving surgery. Tumours were reduced in size by 30-99% in 12 of 22 assigned gefitinib and anastrozole and in 14 of 28 patients assigned gefitinib and placebo.

Professor Coombes comments: "Gefitinib, combined with an aromatase inhibitor, might have a role in the neoadjuvant treatment of breast cancer by reducing the size of the tumour more rapidly. Studies are now being designed to assess this approach."


'"/>

Contact: Joe Santangelo
j.santangelo@elsevier.com
1-212-633-3810
Lancet
16-May-2005


Page: 1

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. Survival differences by race most apparent in advanced stages of breast cancer
3. Stomach cancer rate set to fall further 25 percent over next decade
4. MRI finds breast cancer before it becomes dangerous
5. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
6. New cause of tamoxifen resistance in breast cancer cells discovered at Lombardi
7. Pathway links inflammation, angiogenesis and breast cancer
8. Using MRI for diagnosis could help prevent breast cancer progression
9. Electric fields have potential as a cancer treatment
10. Shining light on pancreatic cancer
11. Method shows promise for early detection of pancreatic cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/19/2019)... ... 19, 2019 , ... NCPDP announced today that Dave deBronkart, ... will deliver the luncheon keynote on Tuesday, May 7, at its 2019 ... empowering partnerships between patients and their medical providers to NCPDP’s Annual Conference, May ...
(Date:2/19/2019)... ... , ... According to a recent study by Columbia University, more than 40% ... and only 26% of widows return to their pre-loss level of life satisfaction, according ... of the most tragic events that one can face. Consequently, many look for a ...
(Date:2/19/2019)... ... February 18, 2019 , ... AdventHealth Connerton is ... Solutions Footwear Sanitizing Stations to maximize infection control for patients and their families. ... as MRSA and C. difficile, which can be transmitted from the bottoms of ...
(Date:2/19/2019)... ... February 19, 2019 , ... ... Create Health, Wealth and Have the Life You Want!” (published by Balboa Press), ... with weight issues to release the pounds, reconnect to their dreams and attain ...
(Date:2/19/2019)... ... February 19, 2019 , ... STAR Institute for ... for occupational therapists beginning March 2019. The focus of the new program is to ... cases. The new Group Supervision Programs will be held on Zoom for five weekly ...
Breaking Medicine News(10 mins):
(Date:2/19/2019)... ... ... ExceleraRx Corporation announced today that St. Luke’s Health System has joined the ... the state of Idaho. , “We are very pleased to welcome St. ... Corp. “We believe St. Luke’s commitment to expanding and leveraging its pharmacy capabilities to ...
(Date:2/19/2019)... ... , ... The Jean Griswold Foundation, a nonprofit named for the founder of ... lives of seniors and others in the communities in which Griswold Home Care operates. ... couldn’t afford them. , “Each of these organizations have made such an ...
(Date:2/19/2019)... , ... February 19, 2019 , ... ... Florida, has completed his new book “Live Hard Die Young.” Dr. Oexner was ... practices chiropractic medicine, therapeutic exercise physiology, and nutritional counseling. Dr. Oexner was a ...
Breaking Medicine Technology:
Cached News: